Cognito Therapeutics is partnering with a nonprofit to “Change the D-Word,” aiming to eliminate the use of “dementia,” a catchall term that can carry stigma. The term “dementia” is an umbrella term ...

Perplexity’s AI search engine encourages users to go deeper with their prompts by engaging in chat sessions that a lawsuit has alleged are often shared in their entirety with Google and Meta without ...

CAMBRIDGE, Mass. and NEW ORLEANS – March 25, 2026 - Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...

New findings highlight correlations between EEG and clinical outcome measures in Alzheimer’s disease Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive ...

Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics announced a $105 million Series C round ...

Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in $105 million in an oversubscribed series C funding round. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge company is on its ...

Cognito Therapeutics, a company using visual and auditory stimulation to treat neurodegenerative disorders, announced it closed an oversubscribed $105 million Series C funding round. Morningside ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Late in 2025, we covered the development of an AI system called Evo that was trained on massive numbers of bacterial genomes. So many that, when prompted with sequences from a cluster of related genes ...